Julia Origüen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5509642/publications.pdf Version: 2024-02-01



ΙΠΠΑ ΟΡΙΟΑΊ/ ΕΝ

#	Article	IF	CITATIONS
1	A Multinational, Preregistered Cohort Study of β-Lactam∫β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
2	Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. American Journal of Transplantation, 2016, 16, 2943-2953.	4.7	104
3	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49
4	T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2018, 73, iv6-iv12.	3.0	47
5	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- 1² -lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
6	Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test. Clinical Microbiology and Infection, 2018, 24, 414-421.	6.0	45
7	Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. Transplant Infectious Disease, 2016, 18, 575-584.	1.7	44
8	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
9	Tocilizumab for the treatment of adult patients with severe COVIDâ€19 pneumonia: A singleâ€center cohort study. Journal of Medical Virology, 2021, 93, 831-842.	5.0	37
10	T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study. Journal of Antimicrobial Chemotherapy, 2018, 73, iv13-iv19.	3.0	31
11	Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enformedades Infecciosas Y Microbiologa Clápica, 2015, 33, 679 e1-679 e21	0.5	29
12	Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in <i>Clostridium difficile</i> Infection: a Retrospective Cohort Study. Journal of Clinical Microbiology, 2019, 57, .	3.9	21
13	Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort. American Journal of Transplantation, 2020, 20, 451-462.	4.7	15
14	Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case–control study. Infection, 2015, 43, 413-422.	4.7	14
15	Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33,	0.5	14
16	600-667. Serum <scp>sCD</scp> 30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation. Transplant Infectious Disease, 2017, 19, e12668.	1.7	13
17	Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study. Transplant International, 2018, 31, 187-197.	1.6	12
18	Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. International Journal of Infectious Diseases, 2021, 105, 487-494.	3.3	11

Julia Origüen

#	Article	IF	CITATIONS
19	Clinical significance of Candida colonization of intravascular catheters in the absence of documented candidemia. Diagnostic Microbiology and Infectious Disease, 2012, 73, 157-161.	1.8	10
20	Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. International Journal of Infectious Diseases, 2021, 105, 319-325.	3.3	10
21	Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. International Journal of Infectious Diseases, 2022, , .	3.3	7
22	T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study—authors' response. Journal of Antimicrobial Chemotherapy, 2019, 74, 533-534.	3.0	4
23	Efficacy and Safety of Oral Fosfomycin for Asymptomatic Bacteriuria in Kidney Transplant Recipients: Results from a Spanish Multicenter Cohort. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	4
24	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transplant Infectious Disease, 2022, 24, e13770.	1.7	3
25	Reply to "Old Habits Die Hard: Screening for and Treating Asymptomatic Bacteriuria After Kidney Transplantation― American Journal of Transplantation, 2016, 16, 3303-3304.	4.7	2
26	Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?. Atherosclerosis, 2018, 269, 204-210.	0.8	2
27	Impact on mortality of adherence to evidence-based interventions in patients with catheter-related bloodstream infection due to methicillin-sensitive Staphylococcus aureus. Infectious Diseases, 2018, 50, 837-846.	2.8	2
28	Early Treatment with Sotrovimab for Covid-19. New England Journal of Medicine, 2022, , .	27.0	1
29	2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study. Open Forum Infectious Diseases, 2019, 6, S936-S936.	0.9	0